Skip to main content
. 2025 Aug 22;17(3):345–351. doi: 10.4274/jcrpe.galenos.2023.2023-7-13

Table 1. Biochemical monitoring of the patient .

Age

Calcitonin(pg/mL)

CEA(ng/mL)

Ca (mg/dL)

P(mg/dL)

ALP(U/L)

PTH(pg/mL)

TSHµIU/mL

FT4pmol/L

S ora fenib (mg/day)

4.2

1093

22.74

9.7

4.3

219

14

3.24

17.95

100

4.9

216

6.1

10.4

4.6

236

15

3.64

21.5

100+100

5.6

119

4.91

9.6

3.17

135

43.5

6.2

21.6

200+100

5.9

41.1

5 . 99

9.8

3.43

155

32

5.31

10.57*

200+100

6.6

67 . 6

3 . 76

10

3.6

151

8.5

7.33

13.2*

200+100

6.9

47

4 . 33

10

5.4

165

92

5.74

14.04*

200+100

7.2

39

3 . 5

9.2

3.8

137

33.5

6.1

11.06*

200+100

8.8

11

2.9

9.4

3.8

152

62.4

6.12

13.61*

200+200

9.6

6.9

2.6

8.9

4.9

167

43

5.18

18.8

200+200

10.1

10

3.14

9

3.9

122

80

3.31

14

200+200

10.5

10.7

1.99

9.4

3.6

175

35

3.62

18

200+200

11.2

9.1

2.54

9.1

3.17

102

19

11**

14

200+200

Normal range for calcitonin: 5.2-11.7 pg/mL, FT4: 11-22 pmol/L, FT4*: 7-15.96 pmol/L, CEA: <0.3ng/mL.

**1.2 mcg/kg/day L-thyroxine treatment initiated.

CEA: carcinoembryonic antigen, Ca: calcium, P: phosphate, ALP: alkaline phosphatase, PTH: parathyroid hormone, TSH: thyroid stimulating hormone, FT4: free thyroxine